Added Value Medicines
Research at Intas is ongoing and with some of the best talent in the Pharmaceutical Industry, our scientists regularly come up with innovative ideas to fulfil the unmet needs of the Pharmaceutical Market.
Fixed-dose combination formulation
Fixed-dose combination (FDC) medicines are medicines containing two or more active components in fixed proportions within a single dosage form. Intas technology includes bilayer and multi-layer tablets. FDC products allow to reduce patient pill-burden, making them more convenient for patients and resulting in improved treatment adherence. Aside from well-known generics, Intas has developed new FDCs (e.g WO2021019493) bringing new treatment solutions to the healthcare system.
One example is Rofencol®, a new FDC bilayer tablet which combines a fixed dose of Rosuvastatin and Fenofibrate. The Dossier of this new FDC added value medicine has been filed in EU in July-2021.
Sustained Release
Oral sustained release (SR) medicines are helpful in reducing dosing frequency to an extent that once daily dosing is sufficient for therapeutic management. This SR technology also provides an improved product efficacy and safety profile due to its reduced fluctuations in drug plasma concentrations. SR medicines are associated with improved treatment compliance and adherence. This SR technology has enabled Intas to build a pipeline of innovative products (e.g., WO 2018051292 & WO2019016686) such as Meniabet TM XR. For this Added Value Medicine, Intas is planning to start a Clinical Phase-III (BERTIGO® – study) in Q1- 2022 in Spain, France, and Germany.
Orally Disintegrating Tablet Technology
This is a drug delivery system designed to provide rapid disintegration of the tablet upon contact with saliva in the mouth. This technology provides a convenient dosage form for patients having impaired swallowing function, patients suffering of drug-induced dysphagia, and in general for paediatric and geriatric patients and for patients having aversion to swallow standard tablets or capsules.
This technology has been applied to our Added Value Medicine, Veloxsol®. Veloxsol® is the first solifenacin ODT marketed in Italy and Australia.
Effervescent Technology
